Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-183175786/research-findings-university-kocaeli.html" title="Facts and information about Research findings from University of Kocaeli update understanding of hyperhomocysteinemia.">Research findings from University of Kocaeli update understanding of hyperhomocysteinemia.</a>
Research findings from University of Kocaeli update understanding of hyperhomocysteinemia.
Women's Health Weekly
|
July 31, 2008 |
COPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright
According to recent research from Umuttepe, Turkey, "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal hepatic steatosis in the absence of a history of alcohol use. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD."
"Hyperhomocysteinemia causes steatosis, and the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms result in hyperhomocysteinemia. To examine whether the C677T and A1298C polymorphisms of the MTHFR gene were associated with NASH, we analysed the allele and genotype distribution of the MTHFR C677T and A1298C polymorphisms in 57 well-diagnosed NASH patients, 324 healthy controls in a case-control study of Turkish subjects of Caucasian origin. The diagnosis of the NASH patients was based on liver biopsy. The method used in the analysis of genotypes was PCR-RFLP. The MTHFR A1298C polymorphism was significantly associated with NASH (chi(2) = 8.439; p = 0.015) in the total NASH patients compared with healthy controls. The MTHFR 1298C allele (odds ratio (OR) = 2.480; 95%CI = 1.286-4.782; chi(2) = 7.703; df = 1; p = 0.006) was significantly associated with NASH in the total NASH patients. The MTHFR C677C/A1298C compound genotype (OR = 2.218; 95%CI = 1.003-4.906; chi(2) = 3.998; df = 1; p = 0.046) in men patients was also significantly associated with NASH. Likewise the MTHFR C1298C genotype was significantly associated with NASH in women patients with NASH (OR = 2.979; 95%CI = 1.027-8.641; chi(2) = 4.343; df = 1; p = ...
Related articles from newspapers, magazines, journals, and more

- Even occasional drinking puts NASH patients at risk.(DIGESTIVE...
- Magazine article from: Family Practice News Sullivan, Michele G. June 15, 2009 700+ words
...patients with nonalcoholic steatohepatitis (NASH), and emphasizes the need for proactive...disease." About 20% of patients with NASH will develop cirrhosis, a proven risk...of HCC in patients with cirrhosis due to NASH." To study this question, Dr. Zein...

- Push diet, exercise; Consider glitazones for NASH: patients who achieved...
- Magazine article from: Internal Medicine News Worcester, Sharon April 15, 2007 700+ words
...higher risk of nonalcoholic steatohepatitis (NASH). For example, about 3% of the general population has NASH, compared with 20%-40% of those with...other factors that have been associated with NASH risk. (See box.) Weight loss is the...

- Occasional drinking may boost liver cancer risk in NASH...
- Magazine article from: Internal Medicine News July 1, 2009 700+ words
...patients with nonalcoholic steatohepatitis (NASH), and emphasizes the need for proactive...disease." About 20% of patients with NASH will develop cirrhosis, a proven risk...of HCC in patients with cirrhosis due to NASH." In a retrospective analysis, he and...

- Sucampo Pharmaceuticals, Inc. Initiates Phase II Study With RU-8811 In...
- Press release article from: PR Newswire September 24, 2002 700+ words
...with non-alcoholic steatohepatitis (NASH) disease. The open-label study, which...Disease Type III and IV, also known as NASH, will be conducted at Innova Fairfax Hospital...Ueno, M.D., Ph.D., Ph.D. "NASH is increasingly recognized as a common...

- Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in...
- Press release article from: PR Newswire October 20, 2008 700+ words
...potential efficacy of cysteamine in NASH patients, UCSD is performing the Phase...expected to enroll 12 adolescent NASH patients who have been managing the disease...clinical studies of cysteamine in NASH patients. Cysteamine is currently cleared...

- Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a...
- Newspaper article from: Hepatitis Weekly February 16, 2009 700+ words
...causes of cirrhosis in the U.S. NASH patients are currently limited to managing...enrolled a total of 12 adolescent NASH patients receiving a twice daily oral dose...clinical trials of cysteamine in NASH patients. Cysteamine, currently cleared...

- NASH treatments controversial, unproven.(GASTROENTEROLOGY)(nonalcoholic...
- Magazine article from: Internal Medicine News Brunk, Doug June 1, 2009 700+ words
...Cleveland Clinic. "Not everyone with NASH [nonalcoholic steatohepatitis...polyunsaturated fatty acids (PUFAs) by NASH patients improved their alanine transaminase...loss and exercise in patients with NASH, but the evidence is incomplete...

- Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in...
- Press release article from: PR Newswire Europe October 12, 2009 700+ words
...are asymptomatic and feel healthy, NASH causes decreased liver function and...trial currently has enrolled eleven NASH patients between 11-18 years old. No major...and principal investigator for the NASH study, stated, "We were encouraged...
For more facts and information, see all results
Source: HighBeam Research, Research findings from University of Kocaeli update understanding of...